Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of reldesemtiv in amyotrophic lateral sclerosis
2018-000586-37Phase 2Completed
- Sponsor
- Cytokinetics
- Start
- May 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in amyotrophic lateral sclerosis (ALS) comparing Reldesemtiv with Placebo (2 arms). Primary endpoint: Change in percent predicted slow vital capacity. Started May 2018; status: completed.
02
Drugs
reldesemtiv
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on 2018-000586-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000586-37.